Top

Published in:

01-02-2019 | Review Article

Gene and miRNA expression in giant cell arteritis—a concise systematic review of significantly modified studies

Authors: Tadeja Kuret, Blaž Burja, Julia Feichtinger, Gerhard G. Thallinger, Mojca Frank-Bertoncelj, Katja Lakota, Polona Žigon, Snezna Sodin-Semrl, Saša Čučnik, Matija Tomšič, Alojzija Hočevar

Published in: Clinical Rheumatology | Issue 2/2019

Abstract

Giant cell arteritis (GCA) is a systemic vasculitis in individuals older than 50 years, characterized by headaches, visual disturbances, painful scalp, jaw claudication, impairment of limb arteries, and systemic inflammation, among other symptoms. GCA diagnosis is confirmed by a positive temporal artery biopsy (TAB) or by imaging modalities. A prominent acute phase response with inflammation is the hallmark of the disease, predominantly targeting large- and medium-sized arteries leading to stenosis or occlusion of arterial lumen. To date, there are no reliable tissue markers specific for GCA. Scarce reports have indicated the importance of epigenetics in GCA. The current systematic review reports significantly changed candidate biomarkers in TABs of GCA patients compared to non-GCA patients using qPCR.

Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B (2017) Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 13(10):578–592. https://doi.org/10.1038/nrrheum.2017.142 CrossRefPubMed

Makol A, Matteson EL (2012) Utility of C-reactive protein in the diagnosis of giant cell arteritis: better than the erythrocyte sedimentation rate? Int J Clin Rheumatol 7(3):247–250CrossRef

De Smit E, Clarke L, Sanfilippo PG, Merriman TR, Brown MA, Hill CL, Hewitt AW (2017) Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence? RMD Open 3(2):e000531. https://doi.org/10.1136/rmdopen-2017-000531 CrossRefPubMedPubMedCentral

Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B (2017) Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 16(8):833–844. https://doi.org/10.1016/j.autrev.2017.05.014 CrossRefPubMed

Guevara M, Kollipara CS (2018) Recent advances in Giant cell arteritis. Curr Rheumatol Rep 20(5):25. https://doi.org/10.1007/s11926-018-0737-1 CrossRefPubMed

Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM (2017) Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 114(6):E970–E979. https://doi.org/10.1073/pnas.1616848114 CrossRefPubMedPubMedCentral

Weyand CM, Berry GJ, Goronzy JJ (2018) The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 103(3):565–575. https://doi.org/10.1189/jlb.3MA0717-283 CrossRefPubMed

Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM (2017) Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312(5):H1052–H1059. https://doi.org/10.1152/ajpheart.00024.2017 CrossRefPubMedPubMedCentral

Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, Ciudad M, Leguy V, Berthier S, Vinit J, Manckoundia P, Maillefert JF, Besancenot JF, Aho-Glele S, Olsson NO, Lorcerie B, Guillevin L, Mouthon L, Saas P, Bateman A, Martin L, Janikashvili N, Larmonier N, Bonnotte B (2012) Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 64(11):3788–3798. https://doi.org/10.1002/art.34647 CrossRefPubMed

10.

van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, Roffel MP, Roozendaal C, Kluin PM, Bos NA, Boots AM, Brouwer E (2014) Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 66(7):1927–1938. https://doi.org/10.1002/art.38625 CrossRefPubMed

11.

Ciccia F, Rizzo A, Ferrante A, Guggino G, Croci S, Cavazza A, Salvarani C, Triolo G (2017) New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev 16(7):675–683. https://doi.org/10.1016/j.autrev.2017.05.004 CrossRefPubMed

12.

Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart R, Whitlock M, Schmidt WA (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636–643. https://doi.org/10.1136/annrheumdis-2017-212649 CrossRefPubMed

13.

Carmona FD, Martin J, Gonzalez-Gay MA (2015) Genetics of vasculitis. Curr Opin Rheumatol 27(1):10–17. https://doi.org/10.1097/BOR.0000000000000124 CrossRefPubMed

14.

Carmona FD, Vaglio A, Mackie SL, Hernandez-Rodriguez J, Monach PA, Castaneda S, Solans R, Morado IC, Narvaez J, Ramentol-Sintas M, Pease CT, Dasgupta B, Watts R, Khalidi N, Langford CA, Ytterberg S, Boiardi L, Beretta L, Govoni M, Emmi G, Bonatti F, Cimmino MA, Witte T, Neumann T, Holle J, Schonau V, Sailler L, Papo T, Haroche J, Mahr A, Mouthon L, Molberg O, Diamantopoulos AP, Voskuyl A, Brouwer E, Daikeler T, Berger CT, Molloy ES, O'Neill L, Blockmans D, Lie BA, McLaren P, Vyse TJ, Wijmenga C, Allanore Y, Koeleman BPC, Barrett JH, Cid MC, Salvarani C, Merkel PA, Morgan AW, Gonzalez-Gay MA, Martin J (2017) A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with Giant cell arteritis. Am J Hum Genet 100(1):64–74. https://doi.org/10.1016/j.ajhg.2016.11.013 CrossRefPubMed

15.

Serrano A, Marquez A, Mackie SL, Carmona FD, Solans R, Miranda-Filloy JA, Hernandez-Rodriguez J, Cid MC, Castaneda S, Morado IC, Narvaez J, Blanco R, Sopena B, Garcia-Villanueva MJ, Monfort J, Ortego-Centeno N, Unzurrunzaga A, Mari-Alfonso B, Sanchez Martin J, de Miguel E, Magro C, Raya E, Braun N, Latus J, Molberg O, Lie BA, Moosig F, Witte T, Morgan AW, Gonzalez-Gay MA, Martin J (2013) Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis 72(11):1882–1886. https://doi.org/10.1136/annrheumdis-2013-203641 CrossRefPubMedPubMedCentral

16.

Bird A (2007) Perceptions of epigenetics. Nature 447(7143):396–398. https://doi.org/10.1038/nature05913 CrossRef

17.

Lai WKM, Pugh BF (2017) Understanding nucleosome dynamics and their links to gene expression and DNA replication. Nat Rev Mol Cell Biol 18(9):548–562. https://doi.org/10.1038/nrm.2017.47 CrossRefPubMedPubMedCentral

18.

Coit P, Direskeneli H, Sawalha AH (2018) An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol 30(1):4–15. https://doi.org/10.1097/BOR.0000000000000451 CrossRefPubMedPubMedCentral

19.

Jeltsch A, Jurkowska RZ (2014) New concepts in DNA methylation. Trends Biochem Sci 39(7):310–318. https://doi.org/10.1016/j.tibs.2014.05.002 CrossRef

20.

Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27. https://doi.org/10.1016/j.cell.2012.06.013 CrossRef

21.

Frank-Bertoncelj M, Gay S (2014) The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis. Arthritis Res Ther 16(3):117. https://doi.org/10.1186/ar4596 CrossRefPubMedPubMedCentral

22.

Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. https://doi.org/10.1038/nrg.2016.59 CrossRef

23.

Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL, Gay S, Tak PP, Prinjha RK, Ospelt C, Reedquist KA (2016) The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 75(2):422–429. https://doi.org/10.1136/annrheumdis-2014-205809 CrossRefPubMed

24.

Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119–1123. https://doi.org/10.1038/nature09589 CrossRefPubMedPubMedCentral

25.

Karlsson O, Baccarelli AA (2016) Environmental health and long non-coding RNAs. Curr Environ Health Rep 3(3):178–187. https://doi.org/10.1007/s40572-016-0092-1 CrossRefPubMedPubMedCentral

26.

Sato F, Tsuchiya S, Meltzer SJ, Shimizu K (2011) MicroRNAs and epigenetics. FEBS J 278(10):1598–1609. https://doi.org/10.1111/j.1742-4658.2011.08089.x CrossRefPubMed

27.

Burja B, Kuret T, Sodin-Semrl S, Lakota K, Rotar Z, Jese R, Mrak-Poljsak K, Zigon P, Thallinger GG, Feichtinger J, Cucnik S, Tomsic M, Praprotnik S, Hocevar A (2018) A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods. Autoimmun Rev 17(2):188–194. https://doi.org/10.1016/j.autrev.2017.11.022 CrossRefPubMed

28.

Lakota K, Feichtinger J, Burja B, Kuret T, Žigon P, Rotar Ž, Ješe R, Sodin-Šemrl S, Čučnik S, Thallinger G, Tomšič M, Hočevar A (2017) Utility of serological parameters in giant cell arteritis for predicting disease complications. Ann Rheum Dis 76:219

29.

Weyand CM, Hicok KC, Hunder GG, Goronzy JJ (1994) Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121(7):484–491CrossRefPubMed

30.

Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121(7):906–915. https://doi.org/10.1161/CIRCULATIONAHA.109.872903 CrossRefPubMedPubMedCentral

31.

Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43(3):294–301. https://doi.org/10.1093/rheumatology/keh058 CrossRef

32.

Ciccia F, Rizzo A, Guggino G, Cavazza A, Alessandro R, Maugeri R, Cannizzaro A, Boiardi L, Iacopino DG, Salvarani C, Triolo G (2015) Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford) 54(9):1596–1604. https://doi.org/10.1093/rheumatology/kev102 CrossRef

33.

Ciccia F, Alessandro R, Rizzo A, Principe S, Raiata F, Cavazza A, Guggino G, Accardo-Palumbo A, Boiardi L, Ferrante A, Principato A, Giardina A, De Leo G, Salvarani C, Triolo G (2011) Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 63(7):2097–2104. https://doi.org/10.1002/art.30374 CrossRefPubMed

34.

Ciccia F, Rizzo A, Maugeri R, Alessandro R, Croci S, Guggino G, Cavazza A, Raimondo S, Cannizzaro A, Iacopino DG, Salvarani C, Triolo G (2016) Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis 76(1):235–243. https://doi.org/10.1136/annrheumdis-2016-209217 CrossRefPubMed

35.

Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, Raiata F, Boiardi L, Cavazza A, Guggino G, De Leo G, Salvarani C, Triolo G (2013) IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis 72(2):258–264. https://doi.org/10.1136/annrheumdis-2012-201309 CrossRefPubMed

36.

Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC (2013) Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 72(9):1481–1487. https://doi.org/10.1136/annrheumdis-2012-201836 CrossRefPubMed

37.

Corbera-Bellalta M, García-Martínez A, Lozano E, Planas-Rigol E, Tavera-Bahillo I, Alba MA, Prieto-González S, Butjosa M, Espígol-Frigolé G, Hernández-Rodríguez J, Fernández PL, Roux-Lombard P, Dayer JM, Rahman MU, Cid MC (2014) Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis 73(3):616–623. https://doi.org/10.1136/annrheumdis-2012-202883 CrossRefPubMed

38.

Lakota K, Kuret T, Žigon P, Rotar Ž, Tomšič M, Čučnik S, Sodin-Šemrl S, Hočevar A (2015) Biomarkers in temporal artery biopsies and sera of patients with giant cell arteritis. Arthritis Rheumatology 67(suppl 10)

39.

Segarra M, García-Martínez A, Sánchez M, Hernández-Rodríguez J, Lozano E, Grau JM, Cid MC (2007) Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 66(11):1429–1435. https://doi.org/10.1136/ard.2006.068148 CrossRefPubMedPubMedCentral

40.

Rodríguez-Pla A, Martínez-Murillo F, Savino PJ, Eagle RC, Seo P, Soloski MJ (2009) MMP-12, a novel matrix metalloproteinase associated with giant cell arteritis. Rheumatology (Oxford) 48(11):1460–1461. https://doi.org/10.1093/rheumatology/kep271 CrossRef

41.

Lozano E, Segarra M, Corbera-Bellalta M, García-Martínez A, Espígol-Frigolé G, Plà-Campo A, Hernández-Rodríguez J, Cid MC (2010) Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis 69(2):434–442. https://doi.org/10.1136/ard.2008.105692 CrossRefPubMed

42.

Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J, Cid MC (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology (Oxford) 50(11):2061–2070. https://doi.org/10.1093/rheumatology/ker163 CrossRef

43.

Manku S, Wong W, Luo Z, Seidman MA, Alabdurubalnabi Z, Rey K, Enns W, Avina-Zubieta JA, Shojania K, Choy JC (2018) IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. Cardiovasc Pathol 33:55–61. https://doi.org/10.1016/j.carpath.2018.01.004 CrossRefPubMed

44.

Zerbini A, Muratore F, Boiardi L, Ciccia F, Bonacini M, Belloni L, Cavazza A, Cimino L, Moramarco A, Alessandro R, Rizzo A, Parmeggiani M, Salvarani C, Croci S (2018) Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology (Oxford) 57(1):64–72. https://doi.org/10.1093/rheumatology/kex334 CrossRef

45.

Regent A, Ly KH, Groh M, Khifer C, Lofek S, Clary G, Chafey P, Baud V, Broussard C, Federici C, Labrousse F, Mesturoux L, Le Jeunne C, Vidal E, Brezin A, Witko-Sarsat V, Guillevin L, Mouthon L (2017) Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation. Autoimmun Rev 16(4):398–406. https://doi.org/10.1016/j.autrev.2017.02.006 CrossRefPubMed

46.

Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH (2016) DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis 75(6):1196–1202. https://doi.org/10.1136/annrheumdis-2014-207116 CrossRefPubMed

47.

Croci S, Zerbini A, Boiardi L, Muratore F, Bisagni A, Nicoli D, Farnetti E, Pazzola G, Cimino L, Moramarco A, Cavazza A, Casali B, Parmeggiani M, Salvarani C (2016) MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. Ann Rheum Dis 75(8):1527–1533. https://doi.org/10.1136/annrheumdis-2015-207846 CrossRefPubMed

48.

Kermani TA, Dasgupta B (2017) Current and emerging therapies in large-vessel vasculitis. Rheumatology. https://doi.org/10.1093/rheumatology/kex385

49.

Ciechomska M, O'Reilly S (2016) Epigenetic modulation as a therapeutic Prospect for treatment of autoimmune rheumatic diseases. Mediat Inflamm 2016:9607946–9607911. https://doi.org/10.1155/2016/9607946 CrossRef

Title: Gene and miRNA expression in giant cell arteritis—a concise systematic review of significantly modified studies
Authors: Tadeja Kuret
Blaž Burja
Julia Feichtinger
Gerhard G. Thallinger
Mojca Frank-Bertoncelj
Katja Lakota
Polona Žigon
Snezna Sodin-Semrl
Saša Čučnik
Matija Tomšič
Alojzija Hočevar
Publication date: 01-02-2019
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 2/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4231-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements

Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren’s syndrome: a retrospective cohort study

Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA

Osteoporosis: a clinical and pharmacological update

Insight into inflammatory cell and cytokine profiles in adult IgA vasculitis

Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials